📊 XGN Key Takeaways
Is Exagen Inc.. (XGN) a Good Investment?
EXAGEN demonstrates strong top-line growth (19.7% YoY) but is experiencing accelerating losses (-32% YoY net income deterioration) with negative operating cash flow of -$13.6M, indicating the business model is not scaling profitably. The combination of 1.31x debt-to-equity leverage, negative free cash flow, and a -30% net margin on $66.6M revenue suggests severe operational inefficiencies despite healthy 58.3% gross margins, creating unsustainable cash burn dynamics.
Why Buy Exagen Inc.. Stock? XGN Key Strengths
- Revenue growth of 19.7% YoY demonstrates market demand for services
- Gross margin of 58.3% indicates core service delivery economics are intact
- Strong liquidity position with current ratio of 3.45x and $32.2M cash reserves
XGN Stock Risks: Exagen Inc.. Investment Risks
- Negative operating cash flow of -$13.6M and free cash flow of -$14.3M indicate unsustainable cash burn
- Net losses accelerating at -32% YoY with -30% net margin despite revenue growth signals operational leverage moving in wrong direction
- Elevated debt-to-equity ratio of 1.31x combined with negative interest coverage (-25.6x) and unprofitable operations creates financial distress risk
- Negative ROE (-114.3%) and ROA (-34.4%) demonstrate severely impaired capital efficiency
- Cash runway of approximately 2+ years at current burn rate creates existential risk without profitability inflection
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Operating margin progression toward profitability
- Revenue retention and customer acquisition costs relative to lifetime value
- Debt reduction progress and interest burden management
Exagen Inc.. (XGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.45x current ratio provides a solid financial cushion.
XGN Profit Margin, ROE & Profitability Analysis
XGN vs Healthcare Sector: How Exagen Inc.. Compares
How Exagen Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exagen Inc.. Stock Overvalued? XGN Valuation Analysis 2026
Based on fundamental analysis, Exagen Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exagen Inc.. Balance Sheet: XGN Debt, Cash & Liquidity
XGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exagen Inc..'s revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.83 indicates the company is currently unprofitable.
XGN Revenue Growth, EPS Growth & YoY Performance
XGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $12.5M | -$3.0M | $-0.28 |
| Q2 2025 | $15.1M | -$3.0M | $-0.16 |
| Q1 2025 | $14.4M | -$3.4M | $-0.19 |
| Q3 2024 | $12.5M | -$3.0M | $-0.28 |
| Q2 2024 | $14.1M | -$3.0M | $-0.16 |
| Q1 2024 | $11.2M | -$3.4M | $-0.19 |
| Q3 2023 | $13.4M | -$5.0M | $-0.31 |
| Q2 2023 | $7.6M | -$5.0M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exagen Inc.. Dividends, Buybacks & Capital Allocation
XGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exagen Inc.. (CIK: 0001274737)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XGN
What is the AI rating for XGN?
Exagen Inc.. (XGN) has an AI rating of STRONG SELL with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XGN's key strengths?
Claude: Revenue growth of 19.7% YoY demonstrates market demand for services. Gross margin of 58.3% indicates core service delivery economics are intact.
What are the risks of investing in XGN?
Claude: Negative operating cash flow of -$13.6M and free cash flow of -$14.3M indicate unsustainable cash burn. Net losses accelerating at -32% YoY with -30% net margin despite revenue growth signals operational leverage moving in wrong direction.
What is XGN's revenue and growth?
Exagen Inc.. reported revenue of $66.6M.
Does XGN pay dividends?
Exagen Inc.. does not currently pay dividends.
Where can I find XGN SEC filings?
Official SEC filings for Exagen Inc.. (CIK: 0001274737) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XGN's EPS?
Exagen Inc.. has a diluted EPS of $-0.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Exagen Inc.. has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XGN stock overvalued or undervalued?
Valuation metrics for XGN: ROE of -114.3% (sector avg: 15%), net margin of -30.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XGN stock in 2026?
Our dual AI analysis gives Exagen Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XGN's free cash flow?
Exagen Inc..'s operating cash flow is $-13.6M, with capital expenditures of $641.0K. FCF margin is -21.4%.
How does XGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30.0% (avg: 12%), ROE -114.3% (avg: 15%), current ratio 3.45 (avg: 2).